NAMPT and adrenal cortex carcinoma: The authors of the recent study found that patients with ACC had significantly higher serum levels of visfatin compared with patients with ACAs, and a visfatin serum concentration of 8.05 ng/mL or higher could potentially be used to discriminate between the two with a sensitivity of 50.0% and a specificity of 92.3% [75].